Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria - Concepedia

Concepedia

Publication | Open Access

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

DOI Full Paper Access

147

Citations

30

References

2013

Year

Joe Bentz, Michael O′Connor, Dallas Bednarczyk, JoAnn Coleman, Caroline Lee, Johan Palm, Y. Anne Pak, Elke S. Perloff, Eric L. Reyner, Praveen Balimane,

Drug Metabolism and Disposition

References

	Year	Citations

Page 1